NovoCure (NVCR) Gross Margin (2014 - 2026)
NovoCure (NVCR) posted quarterly Gross Margin of 77.61% for Q2 2026, up 372.0% year-on-year from 16.44% in Q2 2025, and little changed on a QoQ basis from 77.63% in Q1 2026.
NovoCure (NVCR) Gross Margin (2014 - 2026) Analysis & Trends
NovoCure (NVCR) has reported Gross Margin for 13 consecutive years, with 77.61% the latest figure, recorded in Q2 2026.
- Quarterly Gross Margin rose 372.0% year-over-year to 77.61% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 76.13% (down 26.0% YoY) and the FY2025 annual result came in at 74.54%, down 280.0% from the prior year.
- Gross Margin held at 77.61% in Q2 2026 per NVCR's latest filing, from 77.63% in the prior quarter.
- Over the last five years, Gross Margin for NVCR reached as high as 79.84% in Q1 2022 and fell as low as 73.01% in Q2 2023.
- A 5-year average of 76.45% and a median of 76.39% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin slumped 675 bps — and 2024, when it jumped 394 bps.
- Year by year, Gross Margin stood at 77.51% in 2022, then fell by 2 bps to 75.67% in 2023, then grew by 5 bps to 79.25% in 2024, then decreased by 4 bps to 75.82% in 2025, then gained by 2 bps to 77.61% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 77.61%, 77.63%, and 75.82% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 56.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 63.29% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 65.35% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 69.46% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 78.01% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 62.95% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 45.22% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 38.53% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NovoCure | 2.28 Bn | 1.85 Bn | 142.48 Mn | 77.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.61% |
| Mar 31, 2026 | 77.63% |
| Dec 31, 2025 | 75.82% |
| Sep 30, 2025 | 73.25% |
| Jun 30, 2025 | 73.88% |
| Mar 31, 2025 | 75.15% |
| Dec 31, 2024 | 79.25% |
| Sep 30, 2024 | 77.19% |
| Jun 30, 2024 | 76.95% |
| Mar 31, 2024 | 75.68% |
| Dec 31, 2023 | 75.67% |
| Sep 30, 2023 | 74.79% |
| Jun 30, 2023 | 73.01% |
| Mar 31, 2023 | 75.76% |
| Dec 31, 2022 | 77.51% |
| Sep 30, 2022 | 77.29% |
| Jun 30, 2022 | 79.77% |
| Mar 31, 2022 | 79.84% |
| Dec 31, 2021 | 77.71% |
| Sep 30, 2021 | 77.39% |